Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Journal of Hepatology|January 7, 2015
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infectionPeter Ferenci, Tarik Asselah, Graham R Foster, et al.
Annals of Hepatology|April 7, 2016
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trialsDonald M Jensen, Tarik Asselah, Douglas Dieterich, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 15, 2021
Large-scale screening of lipase acid deficiency in at risk populationAbdellah Tebani, Bénédicte Sudrié-Arnaud, Hela Boudabous, et al.
Journal of Hepatology|February 28, 2025
Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosisPierre Nahon, Clovis Lusivika-Nzinga, Philippe Merle, et al.
Journal of Viral Hepatitis|November 1, 2018
Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohortSegolene Brichler, Pierre Nahon, Fabien Zoulim, et al.
Journal of Hepatology|July 3, 2020
Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV statusEtienne Audureau, Fabrice Carrat, Richard Layese, et al.
Hepatology (Baltimore, Md.)|June 28, 2016
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)Nathalie Ganne-Carrié, Richard Layese, Valérie Bourcier, et al.
Hepatology (Baltimore, Md.)|February 14, 2015
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, et al.
Pageof 7